Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 11:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 453 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Progesterone 100 MG Clear all
Completed Phase 2 Interventional Results available

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

NCT00064025
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Recurrent Uterine Corpus Carcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
Interventions
Laboratory Biomarker Analysis, Medroxyprogesterone, Therapeutic Conventional Surgery
Other · Drug · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 2, 2026, 11:28 AM EDT
Completed Phase 2 Interventional Results available

Neurosteroids as Novel Therapeutic Agents for Chronic Pain in OEF/OIF Veterans

NCT01898013
View directory record Official record
Conditions
Lower Back Pain
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 2, 2026, 11:28 AM EDT
Active, not recruiting Phase 2 Interventional

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

NCT05069038
View directory record Official record
Conditions
Breast Cancer
Interventions
Palbociclib 125mg
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 2, 2026, 11:28 AM EDT
Completed Phase 2 Interventional Results available

Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors

NCT01831076
View directory record Official record
Conditions
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions
Exemestane, Exemestane and tamoxifen
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 2, 2026, 11:28 AM EDT
Completed Not applicable Interventional Results available

Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)

NCT00743574
View directory record Official record
Conditions
Polycystic Ovarian Syndrome, Vitamin D Deficiency
Interventions
Vitamin D2 (Ergocalciferol), Medroxyprogesterone (Provera), Vitamin D3 (Cholecalciferol), Elemental Calcium
Dietary Supplement · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 2, 2026, 11:28 AM EDT
Completed Phase 2 Interventional

Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer

NCT00084396
View directory record Official record
Conditions
Breast Cancer
Interventions
letrozole, conventional surgery
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Oct 2, 2026, 11:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hormonal Birth Control and the Risk of Acquiring HIV

NCT00006324
View directory record Official record
Conditions
HIV Infections
Interventions
Ethinyl estradiol/levonorgestrel, Medroxyprogesterone acetate
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
16 Years to 35 Years · Female only
Enrollment
6,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2002
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2008 · Synced Oct 2, 2026, 11:28 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Kronos Early Estrogen Prevention Study (KEEPS)

NCT00154180
View directory record Official record
Conditions
Menopause, Arteriosclerosis
Interventions
Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo
Drug
Lead sponsor
Kronos Longevity Research Institute
Other
Eligibility
42 Years to 58 Years · Female only
Enrollment
728 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2009 · Synced Oct 2, 2026, 11:28 AM EDT
Terminated Not applicable Interventional Results available

Progestin-induced Endometrial Shedding in PCOS (The PIES in PCOS Study)

NCT01718444
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Infertility
Interventions
Progestin, Clomiphene Citrate
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 2, 2026, 11:28 AM EDT
Completed Not applicable Interventional

Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus

NCT00006133
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
estradiol, ethinyl estradiol, medroxyprogesterone, norethindrone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older · Female only
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 11:28 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Male Hormonal Contraceptive Development-ACY-5

NCT00161447
View directory record Official record
Conditions
Contraception
Interventions
Acyline, Testosterone Gel, Depo-Medroxyprogesterone
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2008 · Synced Oct 2, 2026, 11:28 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Randomized Trial of Cerclage Versus 17 α-Hydroxyprogesterone Caproate for Treatment of a Short Cervix

NCT00694967
View directory record Official record
Conditions
Mid Trimester Cervical Shortening
Interventions
McDonald cerclage placement, 17 hydroxyprogesterone caproate
Procedure · Drug
Lead sponsor
Lehigh Valley Hospital
Other
Eligibility
Female only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2008 · Synced Oct 2, 2026, 11:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hormones and Reduction in Co-users of Marijuana and Nicotine

NCT02579421
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Progesterone, placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 2, 2026, 11:28 AM EDT
Recruiting Phase 2 Interventional

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

NCT06974604
View directory record Official record
Conditions
Breast Neoplasms, Lung Neoplasms
Interventions
Dexamethasone oral
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 2, 2026, 11:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Evaluation of Bioidentical Compounded Estrogen Cream and Natural Progesterone

NCT00864214
View directory record Official record
Conditions
Menopause
Interventions
bioidentical hormone (Biest), bioidentical hormone (Vivelle-Dot)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 16, 2012 · Synced Oct 2, 2026, 11:28 AM EDT
Completed Phase 4 Interventional Results available

Progesterone Augmentation of Nicotine Replacement Therapy Study

NCT02685072
View directory record Official record
Conditions
Smoking Cessation
Interventions
Progesterone (200 mgs BID), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 2, 2026, 11:28 AM EDT
Completed No phase listed Observational

Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105

NCT00959244
View directory record Official record
Conditions
Breast Cancer
Interventions
high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry, medical chart review
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 2, 2026, 11:28 AM EDT
Completed Phase 3 Interventional Results available

Progesterone vs Placebo Therapy for Women With Epilepsy

NCT00029536
View directory record Official record
Conditions
Epilepsy
Interventions
Progesterone Lozenges, Matched Placebo Lozenges
Biological · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
14
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 2, 2026, 11:28 AM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

NCT00592007
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma
Interventions
Fulvestrant and Erlotinib
Drug
Lead sponsor
Lyudmila Bazhenova, M.D.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 2, 2026, 11:28 AM EDT
Completed Early Phase 1 Interventional Results available

PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)

NCT05128071
View directory record Official record
Conditions
Methamphetamine-dependence, Postpartum Abstinence
Interventions
Progesterone, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 2, 2026, 11:28 AM EDT
Terminated Phase 3 Interventional Results available

STRIDE - STimulating Immune Response In aDvanced brEast Cancer

NCT00925548
View directory record Official record
Conditions
Breast Cancer
Interventions
Tecemotide (L-BLP25) and Hormonal Treatment, Placebo of tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl)
Biological · Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 2, 2026, 11:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Sex Hormones on Circadian Rhythm in Men and Women

NCT00001285
View directory record Official record
Conditions
Bipolar Disorder, Circadian Rhythm, Depressive Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Female only
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 11:28 AM EDT
Not listed Phase 2 Interventional

Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA

NCT02064725
View directory record Official record
Conditions
Recurrent or Persistent Endometrial Carcinoma
Interventions
Sodium cridanimod
Drug
Lead sponsor
Kevelt AS
Industry
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
San Jose, California • Santa Rosa, California • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 2, 2026, 11:28 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

NCT02734290
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Pembrolizumab, Paclitaxel, Capecitabine
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 2, 2026, 11:28 AM EDT